Matthew Coleman

Matthew Coleman

Position Title
Adjunct Professor

Department of Radiation Oncology, School of Medicine

2700 Stockton Blvd., Oak Park Research Building, Sacramento, CA

Profile Introduction

I am an adjunct professor of radiation oncology at University of California Davis School of Medicine and senior biomedical staff scientist at Lawrence Livermore National Laboratory. I received my Ph.D. in molecular biochemistry and cellular biology from Boston University. I have authored over 100 publications in peer-reviewed journals, published proceedings and book chapters covering a diverse breadth of molecular biology and biochemistry. I also have over 18 years experience characterizing genomic responses of genotoxic stressors such as ionizing radiation. I also hold five US patents related to biomarker discovery and detection.

Research Interests

Radiation Biology


The major emphasis of my group is a global understanding of the functional genomics of radiation responses as well as other genotoxic stressors. To this end I continue to use genome scale technologies that help to elucidate the initiation and regulation of cellular pathways responsible for determining cell fate in response to primarily low-doses of ionizing radiation (IR) exposures. I have used this approach to elucidate mechanisms associated with low-dose exposures that can be used for applications in biodosimetry. We have developed microarray techniques that are quantitative for identifying and characterizing both RNA and proteins responses in mammalian cells. Importantly, we were among the first groups to identify gene expression responses associated with in vivo low dose exposures in mice and I was the first to characterize the radioadaptive response in human lymphocytes. This work was pivotal in identifying the interplay between cellular proliferation and DNA repair mechanisms to reduce DNA damage in adapting cells. This work has led to looking for biomarkers involved in low dose exposures, radiotherapy and space missions. One example of the current biomarker studies includes looking at optimizing 131I-miBG therapy for children with advance neuroblastoma in collaboration with Dana Farber Cancer Institute. The future development of my research involves aspects of bioinformatics, genomics, and biophysics to address key questions about proteins that play a critical role in modulating as well as mitigating IR induced responses.




My group has also been very active in the development of biotechnology and advance biochemical techniques around the areas of cell-free expression, membrane proteins and nanoparticles made of apolipoproteins called nanolipoproitein particles (NLPs) and detection-based systems. This work involved bioinformatics and statistical processing of genomic and proteomic data. I also worked on device development for pathogen detection using protein microarrays and lateral flow based devices.

Current funding


NIH-NCI- R01CA155642 – Characterization of HER2 family of proteins. Matthew Coleman and Paul Henderson (P.I.s). Total funding level $1,925,000, Jul. 2011 – Jun. 2016

NIH-NCI- R01CA172067. – Optimizing 131I-miBG therapy for children with advance neuroblastoma. Stephan Dubios (P.I.). Total funding level $1,250,000 Aug. 2013 – Jul. 2018.

Synthetic Genomics/LLNL WFO L152281. Cell-free expression and functional testing of MOMP associated with NLP. Matthew Coleman (P.I.). Total funding level $767,000. Mar. 1, 2014- Feb. 31, 2016.

PENDING FUNDING (Awaiting final award letter)

NIH/R01GM117342.  Technology development for biological imaging with x-ray free electron lasers.       Matthias Frank (P.I.). Mar. 2016 – Feb. 2021.

NIAID/NIH, Pilot Study. Characterization of human relevant signatures for internal irradiation. Matthew Coleman (P.I.). April. 2016 – March. 2018

NIAID/ R21AI120925, Synthetic Generation of a Chlamydia Vaccine. Matthew Coleman (P.I.). July. 2016 – Jun. 2018


Grad Group Affiliations

  • Biophysics
  • Pharmacology and Toxicology (PTX)
  • Pharmacology and Toxicology Graduate Group

Honors and Awards

  • Nanotechnology 50 award recipient for cell-free production of nanolipoprotein disc.
  • Merck travel award, Radiation Oncology Gordon Conference.
  • Research and Development 100 award recipient.
  • Stein Moore Graduate Student Award, Protein Society.
  • NIH, Molecular Biophysics Training Grant.

    Professional Societies

    • American Chemical Society
    • Radiation Research Society
    • Protein Society (FASEB)


    • 1997 Ph.D. Molecular and Cellular Biochemistry Boston University


    Geoffrey Feld, Michael Heymann, Henry Benner, Tommaso Pardini, Ching-Ju Tsai, Sebastien Boutet, Matthew Coleman, Mark Hunter, Xiaodan Li, Marc Messerschmidt, Achini Opthalage, Bill Pedrini, Garth Williams, Bryan Krantz, Seth Fraden, Stefan Hau-Riege, James Evans, Brent Segelke and Matthias Frank. (2015) Low-Z polymer sample supports for fixed-target serial femtosecond X-ray crystallography. Journal of Applied Crystallography. 48:1072-1079.

    He, W., Scharadin, T., Saldana, M., Gellner, M., Hoang-Phou, S., Takanishi, C., Hura, G.L., Tainer, J.A., Carraway III, K.A., Henderson, P.T., Coleman, M.A. (2015) Cell-free expression of functional receptor tyrosine kinases. Nature/Scientific Reports. 5:12896. PMID: 26274523

    Coleman, M.A., Sasi, S.P., Onufrak, J., Natarajan, M., Manickam, K., Schwab, J., Peterson, L.E., Alekseyev, Y., Yan, X., Goukassian, D.A. (2015) Delayed Cardiomyocyte Response to Total Body Particle Radiation Exposure – Identification of Regulatory Gene Network. Am J Physiol Heart Circ Physiol. 50. PMID: 26408534.

    Bryan D. Hudson, Nicholas R. Hum, Cynthia B. Thomas, Ayano Kohlgruber, Aimy Sebastian, Nicole M. Collette, Matthew A. Coleman, Blaine Christiansen and Gabriela G. Loots.  (2015) SOST inhibits prostate cancer invasion and metastasis by inhibiting CRIM1 and disrupting cell-cell adhesion. PloS One. 6;10(11). PMID: e0142058.

    Coleman M.A., Cappuccio, J.A., Blanchette, C.D. Arroyo,  E.S., Hinz, A.K., Bourguet, F.A., Hoeprich, P.D., and Chromy, B.A., Reconstitution of the Yersinia pestis, Yop B and YopD translocon complex, facilitated by Nanolipoprotein particles. In press PlosOne.